US Stock Movement | Moderna rises over 6.7% as CDC new guidelines state that COVID-19 vaccination will be based on personal decision

On Wednesday, Moderna's stock price rose, and as of the time of publication, the stock was up over 6.7%, trading at $29.17. In terms of news, the Centers for Disease Control and Prevention (CDC) released the latest immunization schedule for adults and children, for the first time incorporating the COVID-19 vaccine into a "personalized decision" model, and recommending that young children receive the varicella vaccine separately rather than in combination with the measles, mumps, and rubella vaccine. CDC Acting Director and Deputy Secretary of Health and Human Services Jim O’Neill stated that the new policy "brings informed consent back to medical practice." He pointed out that the universal vaccination recommendations in 2022 suppressed the space for doctors and patients to discuss the risks and benefits of vaccines. The new regulations emphasize that among the population under 65, only high-risk individuals have greater benefits from the COVID-19 vaccine, while low-risk individuals can decide whether to get vaccinated in consultation with their doctors